Lido Advisors
GSK icon

Lido Advisors’s GSK GSK Stock Holding History

Lido Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.53M Sell
52,532
-1,347
-3% -$68.8K 0.01% 711
2026
Q2 		$2.83M Buy
53,879
+319
+0.6% +$16.9K 0.01% 681
2026
Q1 		$2.96M Buy
53,560
+7,889
+17% +$427K 0.01% 590
2025
Q4 		$2.21M Buy
45,671
+34,125
+296% +$1.59M 0.01% 689
2025
Q3 		$503K Sell
11,546
-3,192
-22% -$125K ﹤0.01% 1230
2025
Q2 		$572K Buy
14,738
+670
+5% +$25.6K ﹤0.01% 1063
2025
Q1 		$550K Sell
14,068
-8,885
-39% -$325K ﹤0.01% 991
2024
Q4 		$785K Buy
22,953
+1,265
+6% +$45.5K ﹤0.01% 851
2024
Q3 		$887K Sell
21,688
-1,580
-7% -$64.6K ﹤0.01% 757
2024
Q2 		$902K Buy
23,268
+7,677
+49% +$323K 0.01% 699
2024
Q1 		$672K Buy
15,591
+6,795
+77% +$280K ﹤0.01% 791
2023
Q4 		$329K Buy
8,796
+1,440
+20% +$51.7K ﹤0.01% 996
2023
Q3 		$267K Sell
7,356
-334
-4% -$11.9K ﹤0.01% 966
2023
Q2 		$274K Buy
7,690
+156
+2% +$5.6K ﹤0.01% 972
2023
Q1 		$268K Buy
7,534
+92
+1% +$3.22K ﹤0.01% 904
2022
Q4 		$262K Sell
7,442
-4,120
-36% -$137K ﹤0.01% 832
2022
Q3 		$339K Buy
11,562
+2,144
+23% +$81.3K ﹤0.01% 700
2022
Q2 		$512K Sell
9,418
-196
-2% -$10.8K 0.01% 534
2022
Q1 		$523K Sell
9,614
-421
-4% -$22.9K 0.01% 589
2021
Q4 		$553K Sell
10,035
-1,323
-12% -$68.8K 0.01% 576
2021
Q3 		$542K Sell
11,358
-133
-1% -$6.68K 0.01% 564
2021
Q2 		$579K Buy
11,491
+309
+3% +$14.8K 0.01% 506
2021
Q1 		$499K Buy
11,182
+156
+1% +$7.08K 0.01% 500
2020
Q4 		$514K Buy
11,026
+4,778
+76% +$219K 0.01% 472
2020
Q3 		$298K Buy
6,248
+634
+11% +$31.8K 0.01% 492
2020
Q2 		$290K Buy
5,614
+220
+4% +$11.3K 0.01% 454
2020
Q1 		$259K Sell
5,394
-354
-6% -$18.9K 0.01% 449
2019
Q4 		$342K Buy
5,748
+1,556
+37% +$86.6K 0.01% 465
2019
Q3 		$226K Buy
+4,192
New +$216K 0.01% 525

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
JTC Employer Solutions Trustee
JTC Employer Solutions Trustee St Helier, Jersey $1.16B AUM 24.39% 1-Year Est. Return
Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Equity Investment Corp
Equity Investment Corp Atlanta, Georgia $5.3B AUM 8.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Lido Advisors's GSK Position: Q3 2026 in Review

Lido Advisors reduced its GSK (GSK) stake by 2.5% in Q3 2026, selling an estimated $68.8K and leaving 52,532 shares worth $2.53M. The position accounts for 0.01% of the portfolio, ranked #711.

Lido Advisors first reported a position in GSK in Q3 2019 and has held it in 29 quarters since. The position peaked at $2.96M in Q1 2026. 650 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Lido Advisors held 52,532 shares of GSK worth $2.53M as of Q3 2026.
  • Lido Advisors sold 1,347 GSK shares in Q3 2026, an estimated $68.8K.
  • GSK made up 0.01% of Lido Advisors's portfolio in Q3 2026, its #711 holding.
  • Lido Advisors first reported a position in GSK in Q3 2019 and has held it in 29 quarters since.
  • Lido Advisors's GSK position peaked at $2.96M in Q1 2026.
  • 650 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Lido Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.